Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Taiga Miyazaki

Showing results (31-40 of 194) with videos related to

Pageof 20
Sort By:
BMC Nephrology|July 1, 2021
Association between potassium supplementation and the occurrence of acute kidney injury in patients with hypokalemia administered liposomal amphotericin B: a nationwide observational studyYuki Ota, Yoko Obata, Takahiro Takazono, et al.
The Journal of Antimicrobial Chemotherapy|December 22, 2016
Efficacy and pharmacokinetics of ME1100, a novel optimized formulation of arbekacin for inhalation, compared with amikacin in a murine model of ventilator-associated pneumonia caused by Pseudomonas aeruginosaNorihito Kaku, Yoshitomo Morinaga, Kazuaki Takeda, et al.
Antimicrobial Agents and Chemotherapy|May 17, 2017
Efficacy and Pharmacokinetics of the Combination of OP0595 and Cefepime in a Mouse Model of Pneumonia Caused by Extended-Spectrum-Beta-Lactamase-Producing Klebsiella pneumoniaeNorihito Kaku, Kosuke Kosai, Kazuaki Takeda, et al.
Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy|June 29, 2021
Efficacy of early administration of liposomal amphotericin B in patients with septic shock: A nationwide observational studyMasato Tashiro, Takahiro Takazono, Yuki Ota, et al.
Antimicrobial Agents and Chemotherapy|November 2, 2016
Efficacy of High-Dose Meropenem (Six Grams per Day) in Treatment of Experimental Murine Pneumonia Induced by Meropenem-Resistant Pseudomonas aeruginosaKazuhiro Oshima, Shigeki Nakamura, Naoki Iwanaga, et al.
Frontiers in Immunology|November 13, 2024
Antiviral immune response against HTLV-1 invalidates T-SPOT.TB<sup>®</sup> results in patients with HTLV-1-positive rheumatic diseasesMasatoshi Kimura, Kunihiko Umekita, Chihiro Iwao, et al.
BMC Infectious Diseases|October 17, 2015
Clinical characteristics and risk factors of enterococcal infections in Nagasaki, Japan: a retrospective studyToshiki Kajihara, Shigeki Nakamura, Naoki Iwanaga, et al.
Kekkaku : [Tuberculosis]|June 7, 2016
[SERODIAGNOSIS OF THE MYCOBACTERIUM AVIUM COMPLEX BY USING IgA ANTIBODIES FOR THE GLYCOPEPTIDOLIPID CORE ANTIGEN]Yoshitsugu Higashi, Shigeki Nakamura, Hiromi Tomono, et al.
European Journal of Pharmacology|October 12, 2025
OMT-28, a synthetic analog of 17,18-epoxyeicosatetraenoic acid, mitigates lipopolysaccharide-induced lung injury in miceHironobu Tsubouchi, Rika Inomata, Shigehisa Yanagi, et al.
Infection and Immunity|April 20, 2016
Toll-Like Receptor 4 Agonistic Antibody Promotes Host Defense against Chronic Pseudomonas aeruginosa Lung Infection in MiceShigeki Nakamura, Naoki Iwanaga, Masafumi Seki, et al.
Pageof 20

Showing results (31-40 of 194) with videos related to

Sort By:
Pageof 20
BMC Nephrology|July 1, 2021
Association between potassium supplementation and the occurrence of acute kidney injury in patients with hypokalemia administered liposomal amphotericin B: a nationwide observational studyYuki Ota, Yoko Obata, Takahiro Takazono, et al.
The Journal of Antimicrobial Chemotherapy|December 22, 2016
Efficacy and pharmacokinetics of ME1100, a novel optimized formulation of arbekacin for inhalation, compared with amikacin in a murine model of ventilator-associated pneumonia caused by Pseudomonas aeruginosaNorihito Kaku, Yoshitomo Morinaga, Kazuaki Takeda, et al.
Antimicrobial Agents and Chemotherapy|May 17, 2017
Efficacy and Pharmacokinetics of the Combination of OP0595 and Cefepime in a Mouse Model of Pneumonia Caused by Extended-Spectrum-Beta-Lactamase-Producing Klebsiella pneumoniaeNorihito Kaku, Kosuke Kosai, Kazuaki Takeda, et al.
Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy|June 29, 2021
Efficacy of early administration of liposomal amphotericin B in patients with septic shock: A nationwide observational studyMasato Tashiro, Takahiro Takazono, Yuki Ota, et al.
Antimicrobial Agents and Chemotherapy|November 2, 2016
Efficacy of High-Dose Meropenem (Six Grams per Day) in Treatment of Experimental Murine Pneumonia Induced by Meropenem-Resistant Pseudomonas aeruginosaKazuhiro Oshima, Shigeki Nakamura, Naoki Iwanaga, et al.
Frontiers in Immunology|November 13, 2024
Antiviral immune response against HTLV-1 invalidates T-SPOT.TB<sup>®</sup> results in patients with HTLV-1-positive rheumatic diseasesMasatoshi Kimura, Kunihiko Umekita, Chihiro Iwao, et al.
BMC Infectious Diseases|October 17, 2015
Clinical characteristics and risk factors of enterococcal infections in Nagasaki, Japan: a retrospective studyToshiki Kajihara, Shigeki Nakamura, Naoki Iwanaga, et al.
Kekkaku : [Tuberculosis]|June 7, 2016
[SERODIAGNOSIS OF THE MYCOBACTERIUM AVIUM COMPLEX BY USING IgA ANTIBODIES FOR THE GLYCOPEPTIDOLIPID CORE ANTIGEN]Yoshitsugu Higashi, Shigeki Nakamura, Hiromi Tomono, et al.
European Journal of Pharmacology|October 12, 2025
OMT-28, a synthetic analog of 17,18-epoxyeicosatetraenoic acid, mitigates lipopolysaccharide-induced lung injury in miceHironobu Tsubouchi, Rika Inomata, Shigehisa Yanagi, et al.
Infection and Immunity|April 20, 2016
Toll-Like Receptor 4 Agonistic Antibody Promotes Host Defense against Chronic Pseudomonas aeruginosa Lung Infection in MiceShigeki Nakamura, Naoki Iwanaga, Masafumi Seki, et al.
Pageof 20